Study of ONO-8577 in Patients With Overactive Bladder

NCT03106623 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

207

Enrollment

INDUSTRY

Sponsor class

Conditions

Overactive Bladder

Interventions

DRUG: ONO-8577
DRUG: solifenacin succinate + mirabegron
DRUG: Placebo

Sponsor

Ono Pharmaceutical Co., Ltd.